Additionally, GOT1 overexpression reversed the inhibition effects of TMPO-AS1 deficiency on HCC progression, indicating that the TMPO-AS1/miR-429/GOT1 axis may be an underlying treatment strategy for HCC (49). Here, GOT1 is linked to hepatocellular carcinoma.